Do analysts prefer BHC or GUD?

Knight Therapeutics has a consensus price target of C$9.50, suggesting a potential downside of 1.66%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Knight Therapeutics is more favorable than Bausch Health Companies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Companies 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Knight Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings & valuation, GUD or MJN?

Cronos Group has lower revenue, but higher earnings than Knight Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Knight Therapeutics C$547.31M 1.73 -C$30.73M C$0.15 64.40 Cronos Group N/A N/A N/A N/A N/A

Which has higher valuation and earnings, GUD or CRON?

Knight Therapeutics has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Knight Therapeutics C$547.31M 1.73 -C$30.73M C$0.15 64.40 Cronos Group C$179.09M 9.17 -C$32.78M C$0.19 23.47

Do analysts rate CARA or GUD?

Knight Therapeutics has a consensus target price of C$9.50, indicating a potential downside of 1.66%. Given Cara Operations' higher possible upside, equities research analysts clearly believe Cara Operations is more favorable than Knight Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Operations 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Knight Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable valuation & earnings, CARA or GUD?

Cara Operations has higher earnings, but lower revenue than Knight Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cara Operations N/A N/A N/A N/A N/A Knight Therapeutics C$547.31M 1.73 -C$30.73M C$0.15 64.40

Knight Therapeutics (GUD) Competitors

C$9.66 -0.16 (-1.63%)

As of 12:47 PM Eastern

Compare

GUD vs. BHC, MJN, CRON, CARA, and DHT.UN

Should you buy Knight Therapeutics stock or one of its competitors? Knight Therapeutics's main competitors and comparable companies include Bausch Health Companies (BHC), Cronos Group (MJN), Cronos Group (CRON), Cara Operations (CARA), and DRI Healthcare Trust (DHT.UN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Knight Therapeutics compare to Bausch Health Companies?

Bausch Health Companies (TSE:BHC) and Knight Therapeutics (TSE:GUD) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Knight Therapeutics has a net margin of 2.72% compared to Bausch Health Companies' net margin of -12.02%. Bausch Health Companies' return on equity of 87.57% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Companies	-12.02%	87.57%	4.16%
Knight Therapeutics	2.72%	1.91%	0.51%

In the previous week, Bausch Health Companies had 3 more articles in the media than Knight Therapeutics. MarketBeat recorded 3 mentions for Bausch Health Companies and 0 mentions for Knight Therapeutics. Bausch Health Companies' average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score.

Company	Overall Sentiment
Bausch Health Companies	Neutral
Knight Therapeutics	Neutral

Knight Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Companies	C$10.85B	0.33	-C$125.65M	-C$2.94	N/A
Knight Therapeutics	C$547.31M	1.73	-C$30.73M	C$0.15	64.40

10.4% of Bausch Health Companies shares are held by institutional investors. Comparatively, 22.8% of Knight Therapeutics shares are held by institutional investors. 11.3% of Bausch Health Companies shares are held by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Knight Therapeutics has a consensus price target of C$9.50, suggesting a potential downside of 1.66%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Knight Therapeutics is more favorable than Bausch Health Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Companies	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Bausch Health Companies has a beta of 0.959729, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.194384, indicating that its stock price is 119% less volatile than the broader market.

Summary

Knight Therapeutics beats Bausch Health Companies on 10 of the 15 factors compared between the two stocks.

How does Knight Therapeutics compare to Cronos Group?

Knight Therapeutics (TSE:GUD) and Cronos Group (CVE:MJN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Cronos Group has lower revenue, but higher earnings than Knight Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$547.31M	1.73	-C$30.73M	C$0.15	64.40
Cronos Group	N/A	N/A	N/A	N/A	N/A

In the previous week, Cronos Group had 1 more articles in the media than Knight Therapeutics. MarketBeat recorded 1 mentions for Cronos Group and 0 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company	Overall Sentiment
Knight Therapeutics	Neutral
Cronos Group	Neutral

Knight Therapeutics has a net margin of 2.72% compared to Cronos Group's net margin of 0.00%. Knight Therapeutics' return on equity of 1.91% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	2.72%	1.91%	0.51%
Cronos Group	N/A	N/A	N/A

22.8% of Knight Therapeutics shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Knight Therapeutics currently has a consensus target price of C$9.50, suggesting a potential downside of 1.66%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Knight Therapeutics is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Knight Therapeutics beats Cronos Group on 9 of the 10 factors compared between the two stocks.

How does Knight Therapeutics compare to Cronos Group?

Knight Therapeutics (TSE:GUD) and Cronos Group (TSE:CRON) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Knight Therapeutics has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$547.31M	1.73	-C$30.73M	C$0.15	64.40
Cronos Group	C$179.09M	9.17	-C$32.78M	C$0.19	23.47

In the previous week, Cronos Group's average media sentiment score of 0.78 beat Knight Therapeutics' score of 0.00 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Knight Therapeutics	Neutral
Cronos Group	Positive

Cronos Group has a net margin of 38.95% compared to Knight Therapeutics' net margin of 2.72%. Cronos Group's return on equity of 6.46% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	2.72%	1.91%	0.51%
Cronos Group	38.95%	6.46%	-3.73%

Knight Therapeutics has a beta of -0.194384, meaning that its share price is 119% less volatile than the broader market. Comparatively, Cronos Group has a beta of 1.13355, meaning that its share price is 13% more volatile than the broader market.

Knight Therapeutics presently has a consensus price target of C$9.50, indicating a potential downside of 1.66%. Cronos Group has a consensus price target of C$4.92, indicating a potential upside of 10.24%. Given Cronos Group's higher possible upside, analysts plainly believe Cronos Group is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

22.8% of Knight Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of Cronos Group shares are owned by institutional investors. 45.6% of Knight Therapeutics shares are owned by company insiders. Comparatively, 46.4% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cronos Group beats Knight Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Knight Therapeutics compare to Cara Operations?

Cara Operations (TSE:CARA) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

22.8% of Knight Therapeutics shares are owned by institutional investors. 45.6% of Knight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Cara Operations' average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cara Operations	Neutral
Knight Therapeutics	Neutral

Cara Operations has higher earnings, but lower revenue than Knight Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cara Operations	N/A	N/A	N/A	N/A	N/A
Knight Therapeutics	C$547.31M	1.73	-C$30.73M	C$0.15	64.40

Knight Therapeutics has a consensus target price of C$9.50, indicating a potential downside of 1.66%. Given Cara Operations' higher possible upside, equities research analysts clearly believe Cara Operations is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cara Operations	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Knight Therapeutics has a net margin of 2.72% compared to Cara Operations' net margin of 0.00%. Knight Therapeutics' return on equity of 1.91% beat Cara Operations' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cara Operations	N/A	N/A	N/A
Knight Therapeutics	2.72%	1.91%	0.51%

Summary

Knight Therapeutics beats Cara Operations on 8 of the 9 factors compared between the two stocks.

How does Knight Therapeutics compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

DRI Healthcare Trust has a beta of 0.350693, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.194384, meaning that its stock price is 119% less volatile than the broader market.

DRI Healthcare Trust has a net margin of 5.02% compared to Knight Therapeutics' net margin of 2.72%. DRI Healthcare Trust's return on equity of 2.06% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DRI Healthcare Trust	5.02%	2.06%	4.22%
Knight Therapeutics	2.72%	1.91%	0.51%

0.8% of DRI Healthcare Trust shares are held by institutional investors. Comparatively, 22.8% of Knight Therapeutics shares are held by institutional investors. 0.1% of DRI Healthcare Trust shares are held by insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

DRI Healthcare Trust currently has a consensus target price of C$25.20, indicating a potential upside of 41.18%. Knight Therapeutics has a consensus target price of C$9.50, indicating a potential downside of 1.66%. Given DRI Healthcare Trust's stronger consensus rating and higher possible upside, research analysts plainly believe DRI Healthcare Trust is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

DRI Healthcare Trust has higher earnings, but lower revenue than Knight Therapeutics. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DRI Healthcare Trust	C$172.34M	5.69	C$9.73M	-C$0.80	N/A
Knight Therapeutics	C$547.31M	1.73	-C$30.73M	C$0.15	64.40

In the previous week, DRI Healthcare Trust's average media sentiment score of 1.08 beat Knight Therapeutics' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the media.

Company	Overall Sentiment
DRI Healthcare Trust	Positive
Knight Therapeutics	Neutral

Summary

DRI Healthcare Trust beats Knight Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Knight Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GUD vs. The Competition

Export

Metric	Knight Therapeutics	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$948.92M	C$12.45B	C$7.28B	C$12.43B
Dividend Yield	N/A	2.66%	2.55%	6.20%
P/E Ratio	64.40	777.30	268.89	39.80
Price / Sales	1.73	760.07	618.16	9.90
Price / Cash	3.85	96.52	78.23	82.29
Price / Book	1.19	12.02	13.17	4.73
Net Income	-C$30.73M	C$2.81B	C$3.46B	C$299.09M
7 Day Performance	4.89%	0.77%	1.47%	0.11%
1 Month Performance	-1.83%	2.22%	4.60%	5.35%
1 Year Performance	50.70%	7.69%	27.68%	36.99%

Knight Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GUD Knight Therapeutics	N/A	C$9.66 -1.6%	C$9.50 -1.7%	+53.7%	C$948.92M	C$547.31M	64.40	725
BHC Bausch Health Companies	0.4306 of 5 stars	C$8.76 +1.6%	N/A	-12.1%	C$3.28B	C$10.85B	N/A	19,900	Analyst Revision
MJN Cronos Group	N/A	C$12.15 -1.9%	N/A	+0.0%	C$1.73B	N/A	N/A	7,600	News Coverage
CRON Cronos Group	2.2645 of 5 stars	C$4.49 +1.4%	C$4.92 +9.5%	+31.7%	C$1.65B	C$179.09M	23.63	450
CARA Cara Operations	N/A	N/A	N/A	N/A	C$1.62B	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:GUD) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Knight Therapeutics (GUD) Competitors

GUD vs. BHC, MJN, CRON, CARA, and DHT.UN

How does Knight Therapeutics compare to Bausch Health Companies?

Summary

How does Knight Therapeutics compare to Cronos Group?

Summary

How does Knight Therapeutics compare to Cronos Group?

Summary

How does Knight Therapeutics compare to Cara Operations?

Summary

How does Knight Therapeutics compare to DRI Healthcare Trust?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUD vs. The Competition

Knight Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Knight Therapeutics (GUD) Competitors

GUD vs. BHC, MJN, CRON, CARA, and DHT.UN

How does Knight Therapeutics compare to Bausch Health Companies?

Is BHC or GUD more profitable?

Does the media refer more to BHC or GUD?

Which has higher earnings and valuation, BHC or GUD?

Do insiders & institutionals hold more shares of BHC or GUD?

Do analysts prefer BHC or GUD?

Which has more risk & volatility, BHC or GUD?

Summary

How does Knight Therapeutics compare to Cronos Group?

Which has stronger earnings & valuation, GUD or MJN?

Does the media refer more to GUD or MJN?

Is GUD or MJN more profitable?

Do insiders & institutionals hold more shares of GUD or MJN?

Do analysts rate GUD or MJN?

Summary

How does Knight Therapeutics compare to Cronos Group?

Which has higher valuation and earnings, GUD or CRON?

Does the media prefer GUD or CRON?

Is GUD or CRON more profitable?

Which has more volatility & risk, GUD or CRON?

Do analysts prefer GUD or CRON?

Do insiders & institutionals believe in GUD or CRON?

Summary

How does Knight Therapeutics compare to Cara Operations?

Do insiders & institutionals believe in CARA or GUD?

Does the media refer more to CARA or GUD?

Which has preferable valuation & earnings, CARA or GUD?

Do analysts rate CARA or GUD?

Is CARA or GUD more profitable?

Summary

How does Knight Therapeutics compare to DRI Healthcare Trust?

Which has more volatility & risk, DHT.UN or GUD?

Is DHT.UN or GUD more profitable?

Do institutionals and insiders have more ownership in DHT.UN or GUD?

Do analysts rate DHT.UN or GUD?

Which has preferable valuation and earnings, DHT.UN or GUD?

Does the media refer more to DHT.UN or GUD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUD vs. The Competition

Knight Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools